The assay focuses on identifying activators that can restore the tumor suppressor function of the p53 protein, which is often mutated in human cancers. The assay uses a p53-null H1299 lung cancer cell line that is transfected with a temperature-sensitive p53 mutant and a p53-responsive luciferase reporter. The screen evaluates p53-dependent luciferase-reporter expression and enables rapid screening of compounds that could activate p53, potentially providing a new therapy for cancer treatment. Is the molecule effective to this assay?